会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • TREATMENT OF DISEASE STATES WHICH RESULT FROM NEOPLASTIC CELL PROLIFERATION USING PPAR-GAMMA ACTIVATORS AND COMPOSITIONS USEFUL THEREFOR
    • 使用PPAR-GAMMA激活剂和组合物治疗由神经细胞增殖引起的疾病状态
    • WO1998029113A1
    • 1998-07-09
    • PCT/US1997024190
    • 1997-12-29
    • THE SALK INSTITUTE FOR BIOLOGICAL STUDIESEVANS, Ronald, M.TONTONOZ, PeterNAGY, Laszlo
    • THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    • A61K31/20
    • A61K31/44A61K31/12A61K31/19A61K31/192A61K31/205A61K31/445A61K31/557A61K31/5575A61K2300/00
    • In accordance with the present invention, it has been discovered that PPAR gamma is expressed consistently in tissues associated with each of a variety of disease states which result from neoplastic cell proliferation. It has further been discovered that maximal activation of PPAR gamma with exogenous ligand promotes terminal differentiation of primary cells which are otherwise subject to neoplastic cell proliferation. In accordance with another aspect of the invention, it has been discovered that RXR-specific ligands are also potent agents for induction of differentiation of cells expressing the PPAR gamma /RXR alpha heterodimer, and that simultaneous treatment of cells subject to neoplastic cell proliferation with a PPAR gamma -selective ligand, in combination with an RXR-specific ligand, results in an additive stimulation of differentiation. Thus, the effect of neoplastic cell proliferation can be ameliorated by treatment of cells undergoing neoplastic cell proliferation with PPAR gamma agonists, optionally in the further presence of RXR agonists, thereby blocking further proliferation thereof. Accordingly, compounds and compositions which are useful for the treatment of a variety of disease states which result from neoplastic cell proliferation have been identified and are described herein.
    • 根据本发明,已经发现PPARγ在与由肿瘤细胞增殖引起的多种疾病状态中的每一种相关的组织中一致地表达。 进一步发现,外源性配体的PPARγ的最大活化促进原始细胞的终末分化,否则其将受到肿瘤细胞增殖的影响。 根据本发明的另一方面,已经发现RXR特异性配体也是用于诱导表达PPARγ/RXRα异二聚体的细胞分化的有效试剂,并且同时处理具有赘生性细胞增殖的细胞 PPARγ选择性配体与RXR特异性配体组合导致分化的加性刺激。 因此,可以通过用任选地在RXR激动剂的进一步存在下治疗与PPARγ激动剂进行肿瘤细胞增殖的细胞来改善肿瘤细胞增殖的作用,从而阻止其进一步增殖。 因此,已经鉴定并描述了可用于治疗由肿瘤细胞增殖引起的各种疾病状态的化合物和组合物。
    • 8. 发明申请
    • COMPOUNDS, KITS AND METHODS FOR CONFERRING CYTOPROTECTION
    • 化合物,作用和方法进行细胞周期调控
    • WO2007144679A3
    • 2009-06-18
    • PCT/HU2007000055
    • 2007-06-14
    • UNIV DEBRECENNAGY LASZLOSZATMARI ISTVAN
    • NAGY LASZLOSZATMARI ISTVAN
    • A61K45/06A61P35/00
    • A61K45/06A61K49/0021
    • ABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided.
    • ABCG2是ATP结合盒转运蛋白的成员,已被确定为针对内源性和外源性毒性物质的保护性泵。 显示ABCG2在干细胞中以高水平表达,并且在细胞分化期间可变地调节。 本文证明功能性ABCG2通过激活核激素受体PPARg在人单核细胞衍生的树突状细胞中表达。 本研究结果揭示了通过脂质激活转录因子PPARg的外源或内源激活可以实现功能性ABCG2表达上调的机制。 因此,本发明涉及PPARg激动剂和可通过ABCG2运输的细胞毒性药物,肿瘤疾病领域的各种治疗以及包括自体细胞治疗在内的细胞治疗以及试剂盒及其组合物的组合治疗。 还提供了用于保护细胞免受细胞毒性药物的方法。